In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
A clinical guideline update on the prevention or delay of diabetes and associated comorbidities was published in January 2025 by the American Diabetes Association (ADA) Professional Practice Committee. These guidelines, published in Diabetes Care (2025;48(Suppl. 1):S50–S58).
Summary: In 178 adults with T2D (HbA1c 7.0-10.5%) on stable metformin, once-weekly semaglutide (0.25-1.0 mg) for 52 weeks produced numerically…
Summary: In 1,748 adults with T2D (HbA1c 7.5-10.0%) inadequately controlled on basal insulin glargine and metformin, once-weekly semaglutide 1.0 mg…
Summary: In 788 adults with T2D (HbA1c 7.0-10.5%) inadequately controlled on stable metformin, BMI ≥25, once-weekly semaglutide 1.0 mg for…
In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP <120 mm Hg) significantly reduced cardiovascular events compared to standard treatment (systolic BP <140 mm Hg), though it was associated with increased risks of symptomatic hypotension and hyperkalemia.
In adults with type 2 diabetes inadequately controlled with metformin (alone or with sulfonylurea), oral semaglutide (7 mg and 14 mg) significantly reduced HbA1c and body weight compared to sitagliptin over 26 weeks, while the 3 mg dose showed no significant benefit.
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.